Janssen Receives FDA Breakthrough Therapy Designation for Multiple Myeloma mAb
FDA has granted Janssen breakthrough therapy designation for teclistamab, an investigational bispecific antibody under development for treating relapsed or refractory multiple myeloma.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced on June 1, 2021 that FDA has granted breakthrough therapy designation for teclistamab, an off-the-shelf, T-cell redirecting, bispecific antibody, for treating relapsed or refractory multiple myeloma. FDA’s designation follows a priority medicines (PRIME) designation granted by the European Medicines Agency in January this year. In 2020, the European Commission and FDA each granted teclistamab orphan drug designation for the treatment of multiple myeloma.
Teclistamab targets both B-cell maturation antigen (BCMA), which is expressed at high levels on multiple myeloma cells, and CD3 receptors. The bispecific antibody redirects CD3-positive T-cells to BCMA-expressing myeloma cells to induce killing of tumor cells. Results from preclinical studies demonstrated that teclistamab kills myeloma cell lines and bone marrow-derived myeloma cells from heavily pretreated patients. Teclistamab is currently in Phase II clinical development and is also being explored in combination studies.
“We are pleased to have received [b]reakthrough [t]herapy and PRIME [d]esignations for our novel bispecific antibody, teclistamab,” said Peter Lebowitz, MD, PhD, Global Therapeutic Area head, Oncology, Janssen Research & Development, in a company press release. “This program exemplifies our commitment to advancing science for patients living with multiple myeloma, and it builds upon our robust portfolio in this disease.”
Source: Johnson & Johnson
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
